Drug intelligence / Profile preview

camrelizumab + apatinib + etoposide + cisplatin

Development stage: Preclinical
Lead developer: Jiangsu Hengrui Medicine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of camrelizumab (anti-PD-1 monoclonal antibody), apatinib (VEGFR-2 tyrosine kinase inhibitor), and the chemotherapy agents etoposide and cisplatin. This regimen combines immunotherapy, targeted therapy, and cytotoxic chemotherapy approaches. Etoposide is a topoisomerase 2A inhibitor while cisplatin is a platinum-based DNA-damaging agent. The etoposide-cisplatin (EP) combination is a standard chemotherapy regimen for small cell lung cancer.

Targets

TOP2A (DNA topoisomerase II)VEGFR2 (Vascular endothelial growth factor receptor 2)DNAPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on camrelizumab + apatinib + etoposide + cisplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on camrelizumab + apatinib + etoposide + cisplatin.

Explore the full profile